Lexicon Pharmaceuticals | LXRX - Frais De Vente Et D'Administration





Frais De Vente Et D'Administration Changement Date
Abbott USD 3.27B 138M 2026-03
Acadia Pharmaceuticals USD 160.79M 14.06M 2026-03
Agios Pharmaceuticals USD 38.46M 4.51M 2026-03
Akebia Therapeutics USD 23.53M 3.19M 2025-12
Alnylam Pharmaceuticals USD 282.51M 2.55M 2026-03
AstraZeneca USD 5.06B 455M 2026-03
BioMarin Pharmaceutical USD 258.28M 63.92M 2026-03
Coherus Biosciences USD 15M 6.26M 2025-12
Eli Lilly USD 2.93B 198M 2026-03
Esperion Therapeutics USD 39.42M 456K 2025-12
Halozyme Therapeutics USD 46.29M 18.35M 2026-03
Illumina USD 272M 11M 2026-03
Insmed USD 247.26M 34.78M 2026-03
Ironwood Pharmaceuticals USD 33.33M 2.78M 2024-12
J&J USD 6.03B 719M 2026-03
Lexicon Pharmaceuticals USD 3.98M 195K 2025-12
MacroGenics USD 7.94M 1.96M 2025-12
MannKind USD 54.08M 4.33M 2026-03
Merck USD 2.67B 180M 2026-03
Moderna USD 173M 135M 2026-03
Novartis USD 3.14B 296M 2026-03
PTC Therapeutics USD 73.89M 13.31M 2026-03
Puma Biotechnology USD 16.82M 8.15M 2024-09
Sarepta Therapeutics USD 54.03M 51.35M 2026-03
Thermo Fisher Scientific USD 1.8B 179M 2026-03
Ultragenyx Pharmaceutical USD 88M 1000K 2026-03
United Therapeutics USD 156.6M 34M 2026-03
Vanda Pharmaceuticals USD 39.28M 1.71M 2024-12